Citizens Financial Group Inc. RI Sells 465 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Citizens Financial Group Inc. RI has reduced its holdings in Regeneron Pharmaceuticals by 37.1%, now owning 788 shares valued at approximately $500,000 as per its latest SEC filing.
• Regeneron reported strong earnings, with $12.89 earnings per share for the previous quarter, exceeding analyst expectations of $8.43 and showing a 3.6% year-over-year revenue increase.
• A quarterly dividend of $0.88 has been declared for stockholders of record, reflecting an annualized dividend of $3.52 and a yield of 0.6%.

Citizens Financial Group Inc. RI decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 37.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 788 shares of the biopharmaceutical company's stock after selling 465 shares during the period. Citizens Financial Group Inc. RI's holdings in Regeneron Pharmaceuticals were worth $500,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in REGN. Capital International Investors lifted its stake in Regeneron Pharmaceuticals by 41.6% during the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Regeneron Pharmaceuticals by 63.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after acquiring an additional 810,144 shares during the last quarter. Pacer Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 2,296.9% in the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after acquiring an additional 390,374 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its stake in shares of Regeneron Pharmaceuticals by 171.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock valued at $305,311,000 after acquiring an additional 303,785 shares during the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Up 0.6%

REGN stock opened at $563.00 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The business's 50 day moving average price is $536.80 and its two-hundred day moving average price is $599.75. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.73 and a current ratio of 4.60. The company has a market capitalization of $60.78 billion, a price-to-earnings ratio of 14.19, a price-to-earnings-growth ratio of 1.89 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The firm had revenue of $3,675,600 billion for the quarter, compared to the consensus estimate of $3.30 billion. During the same quarter in the prior year, the business earned $11.56 EPS. The business's revenue for the quarter was up 3.6% on a year-over-year basis. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is currently 8.87%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Argus lowered Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. The Goldman Sachs Group lowered their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Truist Financial lowered their target price on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. Canaccord Genuity Group reissued a "buy" rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Finally, Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price for the company. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $841.30.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.